I-High Purity ye-pharmaceutical intermediates β-Nicotinamide Mononucleotide CAS:1094-61-7 Uthutho olukhuselekileyo lokuqinisekisa ukukhutshwa kwezithethe

Umxholo wemveliso

Usebenzisa
I-β-Nicotinamide mononucleotide (NMN) isetyenziselwa ukufunda i-motifs ebophelelayo ngaphakathi kwe-RNA aptamers kunye neenkqubo zokuvula i-ribozyme ezibandakanya i-β-nicotinamide mononucleotide (β-NMN) -i-RNA fragments.I-NMN yi-nucleotide evela kwi-ribose kunye ne-nicotinamide.I-Niacinamide (i-nicotinamide,) iphuma kwi-vitamin B3, eyaziwa ngokuba yi-niacin.) Njenge-precursor ye-biochemical ye-NAD +, inokuba luncedo ekuthinteleni i-pellagra.
I-β-Nicotinamide mononucleotide yindawo ephakathi kwi-biosynthesis ye-nicotinamide adenine dinucleotide (NAD+).I-Nicotinamide phosphoribosyltransferase (i-Nampt) ikhuthaza ukuxinana kwe-nicotinamide nge-5-phosphoribosyl-1-pyrophosphate ukuvelisa i-β-NMN, ethi emva koko iguqulelwe kwi-NAD+ nge-β-NMN adenyltransferase.At 50-MN-beta isetyenzisiwe I-NAD biosynthesis kunye ne-glucose-stimulated insulin secretion in Nampt +/- imodeli yemouse yesifo se-metabolic, ebonisa indima ye-Nampt kwi-β cell function.Ngaphezu koko, kwi-500 mg / kg / ngosuku, kubonisiwe.

Okunye

I-Nicotinamide mononucleotide ("NMN" kunye ne" β- NMN ") yi-nucleotide ephuma kwi-ribose, i-Nicotinamide, i-Nicotinamide nucleoside kunye ne-nicotinic acid. Kubantu, ezininzi ii-enzymes zisebenzisa i-NMN ukuvelisa i-Nicotinamide adenine dinucleotice (i-NADH yayiyi-Inposed). ukuba i-NMN yaxutywa emathunjini amancinci ngaphakathi kwemizuzu ye-10 emva kokulawulwa komlomo kwaye yaguqulwa ibe yiNicotinamide adenine dinucleotide (NAD +) ngokusebenzisa umthuthi we-Slc12a8.

Ngenxa yokuba i-NADH ibe yi-cofactor yeenkqubo zangaphakathi ze-mitochondrial, i-sirtuins, kunye ne-PARP, i-NMN iye yafundwa njenge-neuroprotective enokubakho kunye ne-anti-aging agent kwiimodeli zezilwanyana.Xa amanqanaba e-NAD + enyuka, ukuthintela ukubola kwe-mitochondrial kunokubuyisela umva ukuguga kwinqanaba leselula, okwenza ukuba idume ngokubanzi kwiimveliso ezichasene nokuguga.Iinkampani zezongezo zokutya zikhuthaza ngokukhutheleyo iimveliso ze-NMN, zibanga ukuba zinezi nzuzo.Nangona kunjalo, ukuza kuthi ga ngoku, akukho sifundo somntu sokuqinisekisa ngokuchanekileyo isiphumo saso sokuchasa ukuguga.Uphononongo olwenziwe yiYunivesithi yaseKeio lubonisa ukuba idosi enye ukuya kuthi ga kwi-500 mg ikhuselekile kumadoda.Ngo-2021, ulingo lweklinikhi lwafumanisa ukuba i-NMN yaphucula uvakalelo lwe-insulin yemisipha yabasetyhini abanesifo seswekile, ngelixa olunye ulingo lwezonyango lwafumanisa ukuba luphucule amandla e-aerobic eembaleki ezifundayo.

I-NMN ixhomekeke ngokulula kwi-extracellular degradation yi-CD38 enzymes, enokuthi ivinjwe ngama-compounds afana ne-CD38-IN-78c.